CN1140271C - Medicine for treating vertigo - Google Patents
Medicine for treating vertigo Download PDFInfo
- Publication number
- CN1140271C CN1140271C CNB021223092A CN02122309A CN1140271C CN 1140271 C CN1140271 C CN 1140271C CN B021223092 A CNB021223092 A CN B021223092A CN 02122309 A CN02122309 A CN 02122309A CN 1140271 C CN1140271 C CN 1140271C
- Authority
- CN
- China
- Prior art keywords
- glycerol
- distilled water
- medicine
- vertigo
- sodium chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to medicine for treating vertigo, which is colorless and transparent thick liquid. The medicine is composed of components of the following proportion by weight: 0.81 to 0.99% of trisodium citrate dihydrate, 42.32 to 47.27% of glycerol, 0.20 to 0.25% of sodium chloride and 51.60 to 56.57% of distilled water. The trisodium citrate dihydrate and sodium chloride are dissolved in most of distilled water, and an obtained mixture is added to glycerol and is uniformly mixed by a machine. Then, little residual distilled water is injected in the mixture, and finally, the mixture is uniformly mixed by the machine, which obtains a finished product whose pH value is from 6.5 to 8.5. The present invention has the advantages of scientific and novel component, sufficient raw material, low raw material price, convenient taking, safety, short treatment course, good therapeutic effect and low relapse rate. The medical composition product which is prepared by the method that the trisodium citrate dihydrate and the glycerol are used as active components, and carriers acceptable for pharmacy, diluting agents, auxiliary agents, etc. are matched can carry out the complex of blood calcium ions, reduce cell calcium overloads and dewater so as to avoid discomfortable symptoms of patients because of taking large doses of glycerol. The present invention can effectively treat the pathologic change of the vestibular nervous system taking the vertigo as a main symptom.
Description
Technical field
The present invention relates to pharmaceutical product, relate in particular to a kind of medicine for the treatment of vertigo.
Background technology
Dizzy is a kind of commonly encountered diseases, frequently-occurring disease, difficult disease.Modern medicine study shows have five or six ten kinds of diseases can cause dizzy outbreak.Along with being becoming increasingly acute of the quickening of people's rhythm of life and global environmental problem is outstanding, comprise that the vertigo sickness rate of Meniere has presented ascendant trend.Yet, comprise at all times the method for the various treatment vertigos of operative treatment all having the unsafty defective of curative effect.Key component comprises sodium citrate (Natrii Citras) that belongs to anticoagulant and thrombolytic medicine classification and the medicine that belongs to the glycerol (Glycerinum) of diuretic and dehydrant classification; rarely seen had as (" spermology magazine " 1996 the 10th the 4th phases of volume of the protectant report of sperm behind the freezing rewarming; 213～216 pages), and do not see the report that has as treatment vertigo medicine.
Summary of the invention
For solving the problem that prior art exists, the present invention proposes a kind of medicine for the treatment of vertigo.The technical scheme that adopts is as follows:
The medicine of this treatment vertigo, be to be the water white transparency thick liquid of solvent with the distilled water, feature is its component and be respectively sodium citrate 0.81～0.99% by weight content, glycerol 42.32～47.27%, sodium chloride 0.20～0.25%, distilled water 51.60～56.57%, earlier sodium citrate and sodium chloride are dissolved in most of distilled water, again it is added in the glycerol, even with mechanical mixture, then, remaining fraction distilled water is injected wherein, at last, the reuse mechanical mixture evenly promptly makes finished product, and pH value is 6.5～8.5.
The present invention's beneficial effect against existing technologies is, component science novelty, and the raw material abundance is inexpensive, taking convenience safety, short treating period, good effect, relapse rate is low.This is active component with sodium citrate and two kinds of chemical substances of glycerol, be equipped with the drug regimen Tetramune that pharmaceutically acceptable carrier, diluent, adjuvant etc. are made, energy complexation blood calcium ion, reduce the cell calcium overload, can also dewater, avoid the patient to take heavy dose of glycerol and malaise symptoms occurs, can treat effectively with dizzy is the vestibular nervous system pathological changes of cardinal symptom.
The specific embodiment
A kind of medicine for the treatment of vertigo---diphenidol is to be the water white transparency thick liquid of solvent with the distilled water, and pH value is 6.5～8.5, its component be respectively sodium citrate 0.9%, glycerol 44.8%, sodium chloride 0.2%, distilled water 54.1% by weight content.Be that each component and content are respectively in per 1000 milliliters of diphenidols, sodium citrate 10 grams, weight and Capacity Ratio are glycerol 500 grams of 1.25 grams per milliliters, sodium chloride 2.5 grams, distilled water 604 grams, gross weight 1116.5 restrains.
Earlier sodium citrate and sodium chloride are dissolved in most of distilled water, again it is added in the glycerol, use the Mixing Machine mix homogeneously, then, remaining fraction distilled water is injected wherein, and last, reuse Mixing Machine mix homogeneously promptly makes finished product, the amount of trying to please is 200 milliliters medicine bottle packing, airtight preservation.
Oral on an empty stomach before the vertigo patient diet, day clothes 3 times, each 20～30 milliliters, each 60 milliliters of patient with severe symptoms.The 152 routine vertigo patient clinic trial through the People's Hospital, Chongren County, responder's 144 examples, effective percentage 94.74%, produce effects person's 108 examples wherein, obvious effective rate 71.05%.
Claims (1)
1, a kind of medicine for the treatment of vertigo, be to be the water white transparency thick liquid of solvent with the distilled water, feature is its component and be respectively sodium citrate 0.81～0.99% by weight content, glycerol 42.32～47.27%, sodium chloride 0.20～0.25%, distilled water 51.60～56.57%, earlier sodium citrate and sodium chloride are dissolved in most of distilled water, again it is added in the glycerol, even with mechanical mixture, then, remaining fraction distilled water is injected wherein, at last, the reuse mechanical mixture evenly promptly makes finished product, and pH value is 6.5～8.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021223092A CN1140271C (en) | 2002-06-01 | 2002-06-01 | Medicine for treating vertigo |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021223092A CN1140271C (en) | 2002-06-01 | 2002-06-01 | Medicine for treating vertigo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1385166A CN1385166A (en) | 2002-12-18 |
| CN1140271C true CN1140271C (en) | 2004-03-03 |
Family
ID=4745033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021223092A Expired - Fee Related CN1140271C (en) | 2002-06-01 | 2002-06-01 | Medicine for treating vertigo |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1140271C (en) |
-
2002
- 2002-06-01 CN CNB021223092A patent/CN1140271C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1385166A (en) | 2002-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1111414C (en) | Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases | |
| Kamisako et al. | Interstitial pneumonitis and interferon-alfa. | |
| RU2008122964A (en) | Azithromycin for the treatment of granulomatous pink (red) acne | |
| Zipser et al. | Hypocalcemic tetany due to sodium phosphate ingestion in acute renal failure | |
| Hardman et al. | Hypercalcaemia associated with calcipotriol (Dovonex) treatment. | |
| Walker et al. | Benylin (dextromethorphan) abuse and mania. | |
| Kulig et al. | Levothyroxine overdose associated with seizures in a young child | |
| CN1140271C (en) | Medicine for treating vertigo | |
| Shiba et al. | Hyponatremia with consciousness disturbance caused by omeprazole administration: a case report and literature review | |
| Ellison | Pernicious anemia masked by multivitamins containing folic acid | |
| Hsu et al. | Extreme hyperphosphatemia and hypocalcemic coma associated with phosphate enema | |
| KALES et al. | Effect of divided calcium intake on calcium metabolism | |
| CN1281217C (en) | Use of activated carbon in oral medicinal preparation for hyperthyroidism | |
| Steendijk | The effect of a continuous intravenous infusion of inorganic phosphate on the rachitic lesions in cystinosis | |
| Tambe et al. | Severe hyponatremia secondary to riluzole therapy in amyotropic lateral sclerosis | |
| RU2585097C1 (en) | Method of treating chronic pancreatitis | |
| Wolpaw et al. | The treatment of acute mercury poisoning with sodium formaldehyde sulfoxylate with a review of twenty cases | |
| RU2801087C1 (en) | Method of increasing bone mineral density in patients with osteoporosis and polyneuropathy in type 2 diabetes mellitus | |
| RU2394563C1 (en) | Method of treating psoriasis | |
| EP3693020A1 (en) | Potassium enriched topical formulations for pain relief and sleep aid | |
| LEVER et al. | Action of dihydrotachysterol in chronic pemphigus | |
| CN1562345A (en) | Drug combination including activator for metabolism of brain and free radical scavenger | |
| Rahmani et al. | Accidental intravenous bolus infusion of potassium chloride in a young man with hypokalemic periodic paralysis | |
| Si et al. | Case report: Near-fatal hypermagnesemia resulting from the use of Epsom salts in a patient with normal renal function | |
| SU1674849A1 (en) | Method for treatment of psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |